Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Revenio Group

27,25

 

EUR

 

+0,37 %

14.056 følger denne virksomhed

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Finansielt overblik og estimater
Investor consensus

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Læs mere
Markedsværdi
727,06 mio. EUR
Aktieomsætning
1,28 mio. EUR
P/E (adj.) (25e)
30,2
EV/EBIT (adj.) (25e)
21,72
P/B (25e)
6,05
EV/S (25e)
6,14
Udbytteafkast, % (25e)
1,59 %
Coverage
Anbefaling
Akkumulér
Kursmål
30.00 EUR
Opdateret
30.04.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analytiker

Seneste analyse

Seneste analyse

Released: 30.04.2025

Seneste omfattende analyse

Released: 21.01.2025

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
7.8
2025

Delårsrapport Q2'25

30.10
2025

Delårsrapport Q3'25

Risiko
Business risk
Valuation risk
Lav
Høj
Alle
Analyse
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse15.5.2025, 06.00

Revenio Group Corporation’s Board of Directors resolved on the long-term incentive plan’s performance period 2025–2027

Revenio Group
Selskabsmeddelelse14.5.2025, 13.00

Revenio Group Corporation: Managers' Transactions – Anat Loewenstein

Revenio Group
Selskabsmeddelelse14.5.2025, 13.00

Revenio Group Corporation: Managers' Transactions – Riad Sherif

Revenio Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse14.5.2025, 13.00

Revenio Group Corporation: Managers' Transactions – Heli Lindfors

Revenio Group
Selskabsmeddelelse14.5.2025, 13.00

Revenio Group Corporation: Managers' Transactions – Bill Östman

Revenio Group
Selskabsmeddelelse14.5.2025, 13.00

Revenio Group Corporation: Managers' Transactions – Ann-Christine Sundell

Revenio Group
Selskabsmeddelelse14.5.2025, 13.00

Revenio Group Corporation: Managers' Transactions – Pekka Tammela

Revenio Group
Selskabsmeddelelse14.5.2025, 13.00

Revenio Group Corporation: Transfer of the Company's own shares

Revenio Group
Selskabsmeddelelse14.5.2025, 13.00

Revenio Group Corporation: Managers' Transactions – Arne Boye Nielsen

Revenio Group
Revenio Q1'25: Exemplary performance
Analyse30.4.2025, 11.54 af
Juha Kinnunen

Revenio Q1'25: Exemplary performance

Revenio's Q1 result operationally exceeded our expectations, both in terms of revenue growth and EBIT. The outlook remains unchanged and the trade war does not seem to cause the company greater problems, at least in the light of current information.

Revenio Group
Revenio Interim report 1-3/2025
Videopræsentation29.4.2025, 12.00

Revenio Interim report 1-3/2025

Revenio Group
Selskabsmeddelelse29.4.2025, 06.00

Revenio Group Corporation: Interim report January 1- March 31, 2025

Revenio Group
Pressemeddelelse24.4.2025, 13.00

Modular Finance IR Consensus: Revenio Group – Consensus estimates Q1 2025

Revenio Group
Revenio Q1'25 preview: Risks have increased significantly
Analytikerkommentar22.4.2025, 07.55 af
Juha Kinnunen

Revenio Q1'25 preview: Risks have increased significantly

Revenio will publish its Q1 report next Tuesday at around 9.00 am EEST. We expect revenue and EBIT to grow significantly in a seasonally weak first quarter.

Revenio Group
Pressemeddelelse17.4.2025, 06.00

Invitation to Revenio Group’s audiocast and teleconference call

Revenio Group
Selskabsmeddelelse10.4.2025, 15.00

Resolutions of Revenio Group Corporation's Annual General Meeting 2025 and the organizing meeting of the Board of Directors

Revenio Group
Selskabsmeddelelse10.4.2025, 12.30

Change in the amount of Revenio Group Corporation’s treasury shares

Revenio Group
Analytikerkommentar4.4.2025, 13.23 af
Juha Kinnunen, Atte Riikola, Thomas Westerholm, Pauli Lohi, Rauli Juva, Aapeli Pursimo, Antti Viljakainen

Case: Potential impacts of U.S. import tariffs on Helsinki Stock Exchange companies

The new import duties announced by the United States are causing headaches for several companies on the Helsinki Stock Exchange, in addition to generally weakening the global economic outlook and increasing uncertainty. Under the current US administration, situations can change rapidly, but according to the current plan, the tariffs should come into effect next Wednesday. The indirect effects of the current trade policy, and especially a potentially looming full-blown trade war, are likely to be greater for most companies than the direct effects, but in this compilation, we outline the potential effects of US import duties on various companies and sectors. This is our best estimate of the current impact, but the situation is evolving and uncertainty is now very high.

OptomedRevenio GroupDetection TechnologyNokiaTelesteRapala VMCWärtsiläVaisalaFiskarsHarviaMetsoKalmarGlastonPonsseKoneKonecranesRobitValmetRauteMetsä BoardStora Enso
Analytikerkommentar28.3.2025, 09.27 af
Juha Kinnunen

Revenio: iCare MAIA microperimeter cleared for marketing in the US

As expected, the FDA cleared Revenio's new iCare MAIA microperimeter. Thus, the new iCare MAIA microperimeter is now available for sale in the US, with deliveries starting in mid-April 2025, according to the company.

Revenio Group
Pressemeddelelse28.3.2025, 07.00

U.S. FDA cleared the new iCare MAIA microperimeter

Revenio Group
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.